Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Cost of Revenue came in at $2.0 billion in Q2 2026, down 4.1% YoY from $2.1 billion in Q2 2025, and down 1.09% on a QoQ basis from $2.0 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Cost of Revenue (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Cost of Revenue data on file, last reported at $2.0 billion in Q2 2026.
- Quarterly Cost of Revenue fell 4.1% year-over-year to $2.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.2 billion (down 1.77% YoY) and the FY2025 annual result came in at $8.3 billion, down 1.9% from the prior year.
- Cost of Revenue fell to $2.0 billion in Q2 2026, from $2.0 billion in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $2.2 billion in Q3 2024 to a low of $1.9 billion in Q1 2022.
- A 5-year average of $2.1 billion and a median of $2.1 billion in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue declined 8.7% — and 2024, when it climbed 9.2%.
- Tracing TEVA's Cost of Revenue over 5 years: stood at $2.1 billion in 2022, then declined by 3.41% to $2.0 billion in 2023, then climbed by 3.33% to $2.1 billion in 2024, then dropped by 2.51% to $2.1 billion in 2025, then retreated by 3.26% to $2.0 billion in 2026.
- The last three Cost of Revenue figures came in at $2.0 billion (Q2 2026), $2.0 billion (Q1 2026), and $2.1 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.25 Bn | 7.60 Bn | 397.90 Mn | 98.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Bn |
| Jun 30, 2026 | 1.99 Bn |
| Mar 31, 2026 | 2.01 Bn |
| Mar 31, 2026 | 2.01 Bn |
| Dec 31, 2025 | 2.06 Bn |
| Dec 31, 2025 | 2.06 Bn |
| Sep 30, 2025 | 2.18 Bn |
| Sep 30, 2025 | 2.18 Bn |
| Jun 30, 2025 | 2.07 Bn |
| Jun 30, 2025 | 2.07 Bn |
| Mar 31, 2025 | 2.01 Bn |
| Mar 31, 2025 | 2.01 Bn |
| Dec 31, 2024 | 2.11 Bn |
| Dec 31, 2024 | 2.11 Bn |
| Sep 30, 2024 | 2.18 Bn |
| Sep 30, 2024 | 2.18 Bn |
| Jun 30, 2024 | 2.14 Bn |
| Jun 30, 2024 | 2.14 Bn |
| Mar 31, 2024 | 2.05 Bn |
| Mar 31, 2024 | 2.05 Bn |